FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311088158> ?p ?o ?g. }

• W4311088158 endingPage "609" @default.
• W4311088158 startingPage "599" @default.
• W4311088158 abstract "Gabapentinoids (gabapentin and pregabalin) are widely used in clinical practice, but recent evidence indicates that they carry an increased risk of misuse. As healthcare professionals (HCPs) and policymakers plan different strategies to promote harm reduction, it is important to understand different interested party viewpoints. To explore prescriber, pharmacist, and drug policy expert (DPE) awareness, opinions, and experiences regarding gabapentinoid misuse. A qualitative description study using individual semi-structured virtual interviews was conducted between February and April 2021. Participants included prescribers (physicians, physician assistants [PA], or nurse practitioners [NP]) and pharmacists practicing in outpatient, ambulatory, or community-based healthcare settings; individuals with relevant drug policy expertise were also included. Qualtrics (Provo, Utah) and Zoom (San Jose, California) were used to facilitate quantitative (for initial screening and participant characteristics) and qualitative (interview) data collection. Data were coded and organized into themes in NVivo (QSR International; Burlington, Massachusetts) using thematic analysis steps. A total of 43 individuals participated in this study, including 16 (37.2%) pharmacists, 13 (30.2%) physicians, seven (16.3%) NPs, four (9.3%) DPEs, two (4.7%) pharmacist/DPEs, and one (2.3%) PA. Results were organized along four themes: (1) challenges/opportunities in gabapentinoid use; (2) gabapentinoid misuse awareness; (3) solutions to gabapentinoid misuse and (4) contributing barriers in pain management. Participants invoked different opinions in their consideration of gabapentinoid misuse, including the desire for harm reduction, the limitations of the current healthcare and insurance system, the lack of options for pain and substance use disorder treatment, and the influence of patient expectations. Gabapentinoid misuse was commonly framed in comparative fashion to ongoing concerns with opioids, and proposed solutions often focused less on regulatory control and more toward patient and HCP education and an overhaul of the health system approach to substance use and healthcare overall." @default.
• W4311088158 created "2022-12-23" @default.
• W4311088158 creator A5025416807 @default.
• W4311088158 creator A5063607212 @default.
• W4311088158 creator A5068405817 @default.
• W4311088158 creator A5076090169 @default.
• W4311088158 creator A5030576166 @default.
• W4311088158 date "2023-04-01" @default.
• W4311088158 modified "2023-10-14" @default.
• W4311088158 title "Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse" @default.
• W4311088158 cites W1977980816 @default.
• W4311088158 cites W1979290264 @default.
• W4311088158 cites W1983926592 @default.
• W4311088158 cites W2068374682 @default.
• W4311088158 cites W2106408323 @default.
• W4311088158 cites W2150652573 @default.
• W4311088158 cites W2159165123 @default.
• W4311088158 cites W2217939607 @default.
• W4311088158 cites W2302283005 @default.
• W4311088158 cites W2424370328 @default.
• W4311088158 cites W2583970354 @default.
• W4311088158 cites W2756978732 @default.
• W4311088158 cites W2760847338 @default.
• W4311088158 cites W2771946199 @default.
• W4311088158 cites W2780531213 @default.
• W4311088158 cites W2799766198 @default.
• W4311088158 cites W2885125510 @default.
• W4311088158 cites W2888071069 @default.
• W4311088158 cites W2920827047 @default.
• W4311088158 cites W2925285214 @default.
• W4311088158 cites W2999445018 @default.
• W4311088158 cites W3007986978 @default.
• W4311088158 cites W3019111858 @default.
• W4311088158 cites W3046703154 @default.
• W4311088158 cites W3099018835 @default.
• W4311088158 cites W3117985481 @default.
• W4311088158 cites W3164614050 @default.
• W4311088158 cites W3176662896 @default.
• W4311088158 cites W4200334368 @default.
• W4311088158 cites W4207071162 @default.
• W4311088158 cites W4224212765 @default.
• W4311088158 doi "https://doi.org/10.1016/j.sapharm.2022.12.001" @default.
• W4311088158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36503683" @default.
• W4311088158 hasPublicationYear "2023" @default.
• W4311088158 type Work @default.
• W4311088158 citedByCount "0" @default.
• W4311088158 crossrefType "journal-article" @default.
• W4311088158 hasAuthorship W4311088158A5025416807 @default.
• W4311088158 hasAuthorship W4311088158A5030576166 @default.
• W4311088158 hasAuthorship W4311088158A5063607212 @default.
• W4311088158 hasAuthorship W4311088158A5068405817 @default.
• W4311088158 hasAuthorship W4311088158A5076090169 @default.
• W4311088158 hasConcept C104863432 @default.
• W4311088158 hasConcept C118552586 @default.
• W4311088158 hasConcept C138816342 @default.
• W4311088158 hasConcept C142724271 @default.
• W4311088158 hasConcept C144024400 @default.
• W4311088158 hasConcept C15744967 @default.
• W4311088158 hasConcept C159110408 @default.
• W4311088158 hasConcept C160735492 @default.
• W4311088158 hasConcept C17744445 @default.
• W4311088158 hasConcept C190248442 @default.
• W4311088158 hasConcept C199539241 @default.
• W4311088158 hasConcept C204787440 @default.
• W4311088158 hasConcept C2776468701 @default.
• W4311088158 hasConcept C2776608144 @default.
• W4311088158 hasConcept C2777056318 @default.
• W4311088158 hasConcept C2777363581 @default.
• W4311088158 hasConcept C2779457091 @default.
• W4311088158 hasConcept C36289849 @default.
• W4311088158 hasConcept C512399662 @default.
• W4311088158 hasConcept C529928208 @default.
• W4311088158 hasConcept C71924100 @default.
• W4311088158 hasConcept C74196892 @default.
• W4311088158 hasConcept C77805123 @default.
• W4311088158 hasConceptScore W4311088158C104863432 @default.
• W4311088158 hasConceptScore W4311088158C118552586 @default.
• W4311088158 hasConceptScore W4311088158C138816342 @default.
• W4311088158 hasConceptScore W4311088158C142724271 @default.
• W4311088158 hasConceptScore W4311088158C144024400 @default.
• W4311088158 hasConceptScore W4311088158C15744967 @default.
• W4311088158 hasConceptScore W4311088158C159110408 @default.
• W4311088158 hasConceptScore W4311088158C160735492 @default.
• W4311088158 hasConceptScore W4311088158C17744445 @default.
• W4311088158 hasConceptScore W4311088158C190248442 @default.
• W4311088158 hasConceptScore W4311088158C199539241 @default.
• W4311088158 hasConceptScore W4311088158C204787440 @default.
• W4311088158 hasConceptScore W4311088158C2776468701 @default.
• W4311088158 hasConceptScore W4311088158C2776608144 @default.
• W4311088158 hasConceptScore W4311088158C2777056318 @default.
• W4311088158 hasConceptScore W4311088158C2777363581 @default.
• W4311088158 hasConceptScore W4311088158C2779457091 @default.
• W4311088158 hasConceptScore W4311088158C36289849 @default.
• W4311088158 hasConceptScore W4311088158C512399662 @default.
• W4311088158 hasConceptScore W4311088158C529928208 @default.
• W4311088158 hasConceptScore W4311088158C71924100 @default.
• W4311088158 hasConceptScore W4311088158C74196892 @default.
• W4311088158 hasConceptScore W4311088158C77805123 @default.

• next